Evidence map›Paper›PMID 33402456›Full record

ArticleIn vivo (Athens, Greece)

Felix Zwicker, Henrik Hauswald, Klaus-Josef Weber, JÜrgen Debus, Peter E Huber

Open access · diamondAbstract read
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Felix Zwicker *Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany; f.zwicker@dkfz.de.
Henrik HauswaldDepartment of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
Klaus-Josef WeberDepartment of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
JÜrgen DebusDepartment of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
Peter E HuberDepartment of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
Heidelberg University · DEUniversity Hospital Heidelberg · DEGerman Cancer Research Center · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimCasein kinase 2 (CK2) which sustains multiple pro-survival functions in cellular DNA-damage response, is strictly regulated in normal cells but elevated in cancer. CK2 is considered as a potential therapeutic target, and its inhibition has been associated with radiosensitization in mammalian cells in vitro. Here, we investigated potential radiosensitization by CK2 inhibition in vivo. MATERIALS AND

methodsThe effect of CK2 inhibition in vivo was investigated in human WiDr-xenograft tumours grown subcutaneously on BALB/c nu/nu mice with and without fractionated irradiation. CK2 inhibition was performed using the specific inhibitor tetra-bromobenzotriazole (TBB). Histological examinations included staining for apoptosis and double-strand breaks.

resultsBoth TBB treatment alone and radiation alone significantly reduced tumour growth, which was reflected by increased apoptosis rates. However, TBB treatment did not boost radiation-induced tumour growth suppression in combined treatment, although the apoptosis rate increased and repair of double-strand breaks was reduced. This was in stark contrast to previous data on in vitro radiosensitization.

conclusionThe absence of radiosensitization by CK2 inhibition should be investigated in different tumour models.

Indexed as

Casein Kinase IINeoplasmsAnimalsApoptosisCell Line, TumorHumansMiceMice, Inbred BALB CMice, NudeCasein Kinase IICK2 inhibitionhuman WiDr tumoursirradiationTBBtetra-bromobenzotriazole

Identifiers

PMID33402456
PMCPMC7880802
OpenAlexW3118297035

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.